Vertex Pharmaceuticals Inc (LTS:0QZU)
$ 469.77 -0.73 (-0.16%) Market Cap: 120.84 Bil Enterprise Value: 116.02 Bil PE Ratio: 0 PB Ratio: 7.74 GF Score: 91/100

Vertex Pharmaceuticals Inc to Discuss VX-864 Phase 2 Results and Alpha-1-Antitrypsin Deficiency (AATD) Program Update Call Transcript

Jun 10, 2021 / 08:30PM GMT
Release Date Price: $215.98 (+0.75%)
Operator

Good day, and thank you for standing by. Welcome to the Vertex Pharmaceuticals VX-864 Phase II Results Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Michael Partridge. Please go ahead. .

Michael Partridge
Vertex Pharmaceuticals Incorporated - SVP of IR

Thank you. Good afternoon. This is Michael Partridge of Vertex. On today's call, we will discuss results from the Phase II clinical study with our investigational Z-AAT corrector, VX-864, for the treatment of alpha-1 antitrypsin deficiency or AATD. Dr. Reshma Kewalramani, Vertex' CEO and President, will provide prepared remarks on the call today. Dr. David Altshuler, Vertex' Head of Global Research and Chief Scientific Officer, will join for Q&A. We expect today's call to run for approximately 30 minutes, and we intend to conclude the call at 5 p.m.

We recommend that you access the webcast slides as you listen to this call. This call is being recorded. A replay will be available on the Vertex website.

We will make forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot